Quick Answer
Traws Pharma, Inc. reported Cash and Equivalents of $21.40 million for fiscal year 2016.
Traws Pharma, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2016 | $21.40M | +8.1% |
| 2015 | $19.80M | -54.6% |
| 2014 | $43.58M | -27.4% |
| 2013 | $60.01M | -26.4% |
| 2012 | $81.53M | +2905.0% |
| 2011 | $2.71M | -63.0% |
| 2010 | $7.34M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2017 | $7.60M | -70.5% | -49.3% |
| June 30, 2017 | $14.99M | +16.9% | -2.6% |
| March 31, 2017 | $15.39M | -8.6% | -28.1% |
| December 31, 2016 | $21.40M | +8.1% | -17.0% |
| September 30, 2016 | $25.78M | +16.1% | -6.6% |
| July 31, 2016 | $27.60M | — | +115.3% |
| June 30, 2016 | $12.82M | -49.5% | -23.9% |
| March 31, 2016 | $16.84M | -50.0% | -15.0% |
- Traws Pharma, Inc. showed an increase of +8.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2016 period, Traws Pharma, Inc.’s cash and equivalents has grown by 191.6% (from $7.34 million to $21.40 million).
- The most recent figure is from Traws Pharma, Inc.’s fiscal year 2016 report (Form 10-K), filed with the SEC on March 29, 2017.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: